Starting Nov. 13, the long-running ACR@Work newsletter is transforming into The Rheum Advocate, delivering the latest updates on advocacy, policy developments, clinical practice support and the issues that matter most to rheumatology professionals.
The ACR has expert guidance for states applying for the Rural Health Transformation Program, including recommendations on policies designed to improve healthcare delivery, strengthen the workforce and ensure patient access to rheumatology care.
The Association for Rheumatology Professionals (ARP) celebrates 60 years & the Rheumatology Research Foundation marks 40 years of advancing patient care & research.
The 2026 Community Practice Innovation Award supports projects that enhance care delivery, improve outcomes and address real-world challenges in rheumatology.
The ACR’s delegation to the American Medical Association’s House of Delegates is gearing up for the HOD Interim Meeting, slated for Nov. 14–18. Several members share their views on the value of this advocacy work and top issues this fall.
The FDA has approved a new drug application for TNX-102 SL (Tonmya), a tablet with 2.8 mg of cyclobenzaprine HCl, after two clinical trials demonstrated the safety and effectiveness of the treatment in adults with fibromyalgia.